Breast Cancer Research and Treatment

, Volume 75, Issue 3, pp 203–212

Mitogenic Properties of Insulin-Like Growth Factors I and II, Insulin-Like Growth Factor Binding Protein-3 and Epidermal Growth Factor on Human Breast Epithelial Cells in Primary Culture

  • Karen S. Strange
  • Darcy Wilkinson
  • Joanne T. Emerman
Article

Abstract

Insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II) are growth factors implicated in mammary gland development and are believed to be involved in breast cancer. However, the interactions between components of the IGF system and breast epithelial cells, which give rise to breast cancer, are not well understood. We have investigated the mitogenic properties of IGF-I, IGF-II, IGF binding protein-3 (IGFBP-3) and epidermal growth factor (EGF) on human breast epithelial cells (HBEC) in primary culture. We show that, under serum-free conditions, HBEC are stimulated to grow in response to IGF-I and IGF-II in a dose-dependent manner. IGF-I and EGF, a potent stimulator of HBEC growth in primary culture and also associated with breast cancer, appear to stimulate HBEC in a synergistic manner. IGFBP-3 inhibits the stimulation by IGF-I, IGF-II and IGF-I plus EGF. In addition, it appears that IGFBP-3 has an inhibitory effect on HBEC growth that is IGF-independent. This study is the first to address the effects of IGF-I, IGF-II and IGFBP-3 alone and in combination with EGF on HBEC growth in primary culture. Characterizing the role of the IGF system in normal breast biology is significant because the system has been implicated in breast cancer and a number of the anti-estrogens used in treatment are believed to function through the IGF system.

breast epithelial cells epidermal growth factor insulin-like growth factors I and II insulin-like growth factor binding protein-3 primary culture 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Emerman JT, Wilkinson DA: Routine culturing of normal, dysplastic and malignant human mammary epithelial cells from small tissue samples. In Vitro Cell Dev Biol 26: 1186–1194, 1990Google Scholar
  2. 2.
    Krywicki RF, Yee DR: The insulin-like growth factor family of ligands, receptors and binding proteins. Br Cancer Res Treat 22: 7–19, 1992Google Scholar
  3. 3.
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396, 1998Google Scholar
  4. 4.
    Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 29A: 492–497, 1993Google Scholar
  5. 5.
    Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growth factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 62: 266–270, 1995Google Scholar
  6. 6.
    Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SA, Ramasharma K, Marshall M, Li CH: Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF1 receptor. Mol Endocrinol 3: 1701–1709, 1989Google Scholar
  7. 7.
    De Leon DD, Wilson DM, Powers M, Rosenfeld RG: Effects of insulin-like growth factors (IGFs) and IGF receptor antibod-ies on the proliferation of human breast cancer cells. Growth Factors 6: 327–336, 1992Google Scholar
  8. 8.
    Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB: Human breast cancer cells secrete an insulin-like growth factor-1-related polypeptide. Cancer Res 46: 4613–4619, 1986Google Scholar
  9. 9.
    Westley B, May FEB: IGFs and control of cell proliferation in human breast and other cancers. Rev Endocr-relat Cancer 39: 29–34, 1991Google Scholar
  10. 10.
    Baxter RC, Maitland JE, Raisur RL, Reddel R, Sutherland RL: High molecular weight somatomedin-C (IGF-I) from T47D human mammary carcinoma cells: immunoreactivity and bioactivity. In: Spencer EM (ed) Insulin-like Growth Factors/Somatomedins. De Gruyter, Berlin, 1983, pp 615–618Google Scholar
  11. 11.
    Jones J, Clemmons D: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3–34, 1995Google Scholar
  12. 12.
    Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein 3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237: 690–693, 1997Google Scholar
  13. 13.
    Huynh H, Yang X, Pollak M: Estradiol and antiestrogens reg-ulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016–1021, 1996Google Scholar
  14. 14.
    Stingl J, Eaves CJ, Emerman JT: Characterization of nor-mal human breast epithelial cell subpopulations isolated by flourescence-activated cell sorting and their clonogenic growth in vitro. In: Ip MM, Asch BB (eds) Methods in Mammary Gland Biology and Breast Cancer Research. 2000, pp 177–193Google Scholar
  15. 15.
    Landegren U: Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Meth 67: 379–388, 1984Google Scholar
  16. 16.
    Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA: Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Med 3: 1141–1144, 1997Google Scholar
  17. 17.
    Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem 268: 14964–14971, 1993Google Scholar
  18. 18.
    Piccart MJ, Awada A: State-of-the-art chemotherapy for ad-vanced breast cancer. Semin Oncol 27: 3–12, 2000Google Scholar
  19. 19.
    Winston R, Kao PC, Kiang DT: Regulation of insulin-like growth factors by antiestrogen. Br Cancer Res Treat 31 107–115, 1994Google Scholar
  20. 20.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. JNCI 90: 1371–1388, 1998Google Scholar
  21. 21.
    Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97, 1998Google Scholar
  22. 22.
    Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 358: 98–101, 1998Google Scholar
  23. 23.
    Colletti RB, Roberts JD, Devlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882–1884, 1989Google Scholar
  24. 24.
    Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R: Effects of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. JNCI 82: 1693–1697, 1990Google Scholar
  25. 25.
    De Marinis L, Mancini A, Izzi D, Bianchi A, Giampietro A, Fusco A, Liberale I, Rossi S, Valle D: Inhibitory action of GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer. Clin Endocrinol 52: 681–685, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Karen S. Strange
    • 1
  • Darcy Wilkinson
    • 1
  • Joanne T. Emerman
    • 1
  1. 1.Department of Anatomy, Faculty of MedicineUniversity of British ColumbiaVancouverCanada

Personalised recommendations